TY - JOUR
AU - Bozorgmehr,, Jafar
AB - Seizures occur in ∼5% of people, and recur in >20% of that 5% (1)(2). The etiologies of most seizures are unknown, and head trauma is implicated in only 5–10% of cases (3). Blood or blood components, specifically iron, may be etiologically important; intracranial injection of hemoglobin (4), lysed erythrocytes (5), iron-containing proteins (5), or iron salts (6) produced chronic focal spike activity in rodents and cats. Because microhemorrhagic events occur in the central nervous system of all people, inadequate clearance of iron-rich (7) hemoglobin might underlie development of some seizure disorders. Haptoglobin binds free hemoglobin and removes it from the circulation (8), thus preventing iron loss and kidney damage during hemolysis (9). Haptoglobin contains β- (heavy; 40 kDa) and α- (light; α1 = 8.9 kDa and α2 = 16 kDa) chains. Humans are polymorphic for haptoglobin, with three major phenotypes: Hp 1-1, Hp 2-2, and the heterozygous Hp 2-1 (10). The β-chains are identical in all, with variations dependent on different α-chains. Hp 1-1 expresses only the α1-chain and is the smallest form (86 kDa). Hp 2-1 and Hp 2-2 express α2-chains, which can form polymers of 86–300 kDa (Hp 2-1) and up to 900 kDa (Hp 2-2) (10). Hp 1-1 is biologically the most effective in binding free hemoglobin and suppressing inflammatory responses associated with extracellular (free) hemoglobin (9). In contrast, Hp 2-2 is the least effective (11). The plasma concentrations of haptoglobin are highest in individuals with Hp 1-1 and lowest in those with Hp 2-2, with intermediate concentrations in Hp 2-1 individuals (9). Haptoglobin also has antioxidant (12), angiogenic (13), and antiinflammatory effects (11)(14). Furthermore, haptoglobin has a role in regulation of immune responses (15) by suppressing release of cytotoxins from T-helper type 2 cells and regulating T-helper type 1/T-helper type 2 balance (15). If hemoglobin (or its iron) is involved in the etiology of seizures, then inadequate removal of hemoglobin (by haptoglobin) may be important. We postulated that functional differences between the haptoglobin phenotypes might be related to the severity and frequency of seizure attacks in patients with epilepsy. In this study, we investigated the serum concentrations of haptoglobin and the distribution of haptoglobin phenotypes in people with and without epilepsy and examined the relationship of haptoglobin phenotypes with C-reactive protein (CRP), which, like haptoglobin, is an acute-phase protein. We studied 92 patients (59 men and 33 women), with a mean age of 43 (range, 21–87) years, who had one or more idiopathic seizures per month and who were treated at our medical center. Controls were 100 volunteers (62 men and 38 women), with a mean age of 44 years. No participants had intravascular hemolysis, liver disease, or trauma. The diagnosis of recurrent idiopathic epilepsy was based on clinical status and electroencephalography results. The study was approved by the local Institutional Review Board. Phenotyping of haptoglobin was performed by gel electrophoresis followed by peroxidase staining (16). Mobilities of haptoglobin in the samples were compared with authentic samples of Hp 1-1 and Hp 2-2 for phenotype identification. Concentrations of haptoglobin and CRP (17) were measured by fixed-time immunonephelometry with reagents and instrumentation from Dade Behring. Data are presented as the mean (SE). We used the t-test with Welch’s correction to assess significance of differences of means. Analysis of differences in haptoglobin phenotype distributions in patients and controls was done by χ2 test. Haptoglobin phenotype 2-2 was significantly associated with recurrent seizures (P <0.001), being present in 67% of the patients and in only 35% of controls. Hp 2-1 and 1-1 were present in 18% and 13% of patients, respectively, and in 50% and 15% of controls. Haptoglobin was undetectable in two patients (2%). The distributions of haptoglobin types were in Hardy–Weinberg equilibrium. The association of Hp 2-2 with seizure attacks persisted when patients were compared with ethnically matched controls (Tables 1 and 2 in the Data Supplement that accompanies the online version of this Technical Brief at http://www.clinchem.org/content/vol50/issue6/; P <0.05). Haptoglobin concentrations were significantly higher (P <0.0001) in patients [1.41 (0.08) g/L] than in controls [1.04 (0.04) g/L]. Serum haptoglobin concentrations in patients differed significantly from concentrations in controls when analyzed in relation to their phenotypes (Table 1 ). Table 1. Serum haptoglobin and CRP concentrations according to haptoglobin phenotype in patients and controls. Haptoglobin phenotype . Mean (SE) haptoglobin, g/L . . Mean (SE) CRP, mg/L . . . Patients . Controls . Patients . Controls . Hp 2-2 1.31 (0.08)1 1.01 (0.09) 11.4 (2.1)2 2.38 (0.7) (n = 62) (n = 35) (n = 58) (n = 33) Hp 2-1 1.62 (0.27)3 1.03 (0.05) 7.6 (1.9)4 0.93 (0.2) (n = 11) (n = 50) (n = 16) (n = 51) Hp 1-1 1.71 (0.24)5 1.16 (0.1) 5.8 (2.1)6 0.6 (0.1) (n = 12) (n = 15) (n = 9) (n = 15) Haptoglobin phenotype . Mean (SE) haptoglobin, g/L . . Mean (SE) CRP, mg/L . . . Patients . Controls . Patients . Controls . Hp 2-2 1.31 (0.08)1 1.01 (0.09) 11.4 (2.1)2 2.38 (0.7) (n = 62) (n = 35) (n = 58) (n = 33) Hp 2-1 1.62 (0.27)3 1.03 (0.05) 7.6 (1.9)4 0.93 (0.2) (n = 11) (n = 50) (n = 16) (n = 51) Hp 1-1 1.71 (0.24)5 1.16 (0.1) 5.8 (2.1)6 0.6 (0.1) (n = 12) (n = 15) (n = 9) (n = 15) a–f Compared with controls: 1 P = 0.01; 2 P = 0.0001, 3 P = 0.02; 4 P = 0.0018; 5 P = 0.03; 6 P = 0.022. Open in new tab Table 1. Serum haptoglobin and CRP concentrations according to haptoglobin phenotype in patients and controls. Haptoglobin phenotype . Mean (SE) haptoglobin, g/L . . Mean (SE) CRP, mg/L . . . Patients . Controls . Patients . Controls . Hp 2-2 1.31 (0.08)1 1.01 (0.09) 11.4 (2.1)2 2.38 (0.7) (n = 62) (n = 35) (n = 58) (n = 33) Hp 2-1 1.62 (0.27)3 1.03 (0.05) 7.6 (1.9)4 0.93 (0.2) (n = 11) (n = 50) (n = 16) (n = 51) Hp 1-1 1.71 (0.24)5 1.16 (0.1) 5.8 (2.1)6 0.6 (0.1) (n = 12) (n = 15) (n = 9) (n = 15) Haptoglobin phenotype . Mean (SE) haptoglobin, g/L . . Mean (SE) CRP, mg/L . . . Patients . Controls . Patients . Controls . Hp 2-2 1.31 (0.08)1 1.01 (0.09) 11.4 (2.1)2 2.38 (0.7) (n = 62) (n = 35) (n = 58) (n = 33) Hp 2-1 1.62 (0.27)3 1.03 (0.05) 7.6 (1.9)4 0.93 (0.2) (n = 11) (n = 50) (n = 16) (n = 51) Hp 1-1 1.71 (0.24)5 1.16 (0.1) 5.8 (2.1)6 0.6 (0.1) (n = 12) (n = 15) (n = 9) (n = 15) a–f Compared with controls: 1 P = 0.01; 2 P = 0.0001, 3 P = 0.02; 4 P = 0.0018; 5 P = 0.03; 6 P = 0.022. Open in new tab Because haptoglobin is an acute-phase protein, we measured serum CRP in all participants. CRP was significantly higher in patients than in controls [10.1 (1.5) and 1.4 (0.3) mg/L, respectively; P <0.0001]. Not only was pooled serum CRP significantly different in patients vs controls, but also in individual phenotypes (Table 1 ). In addition, we found statistically significant correlations between serum CRP and haptoglobin concentrations within each individual phenotype, that is, in the Hp 2-2, Hp 2-1, and Hp 1-1 groups individually (r = 0.99). The role of iron and its oxidative capabilities in tissue damage is well documented (18), and iron-containing proteins such as hemoglobin can initiate or enhance oxidative processes (19). Increased accumulation of iron in the brain and defective antioxidant defenses have been linked to both Parkinson and Alzheimer diseases (19). We previously showed that hypohaptoglobinemia was associated with high incidence and frequency of seizures in patients with idiopathic familial epilepsy (20). Defective haptoglobin-mediated clearance of free hemoglobin from the central nervous system could lead to hemoglobin-dependent central nervous system damage. The major hazard posed by iron-containing compounds is in facilitating the formation of reactive oxygen species (21)(22). Hemoglobin, in the presence of a source of superoxide anions and hydrogen peroxide, can catalyze the formation of one or more reactive species resembling hydroxyl radicals (22). Free hemoglobin also enhances the peroxidation of purified arachidonic acid and other polyunsaturated fatty acids within normal cell membranes (23). Furthermore, purified hemoglobin or crude erythrocyte lysates, in the absence of superoxide anions or hydrogen peroxide, cause rapid peroxidation of crude murine brain homogenate (24). CRP is a marker for inflammatory processes, tissue damage, and infection (25). The increase in CRP in our patients suggests that they suffered from inflammation in addition to their seizure disorders. Although we found a correlation between different haptoglobin phenotypes and serum CRP, we do not know whether there is a direct association between inflammation and the pathogenesis of seizure disorders. Haptoglobin is a marker for inflammation (9), and it also was increased. We believe that identification of haptoglobin phenotypes in addition to analysis of serum haptoglobin concentrations may better identify the presence of inflammation: a Hp 2-2 phenotype may indicate the presence of an inflammatory process because Hp 2-2 is more associated with inflammation than Hp 2-1 or Hp 1-1. Indeed, Hp 2-2 type has been associated with several clinical conditions, such as atherosclerosis, cancer, infection, and neurologic disorders (11)(26). In addition, Hp 2-2 complexed with free hemoglobin has a high affinity for CD 163 receptors on macrophages (27). Furthermore, it has been suggested that the uptake and internalization of haptoglobin–hemoglobin complex by macrophages leads to increased oxidative stress in macrophages and, more importantly, delocalization of iron (28), which can further enhance oxidative stress via generation of reactive oxygen species. Although one report denies the enhanced oxidative stress in macrophages after internalization of haptoglobin–hemoglobin complex (29), most of the data in this field support the association of Hp 2-2 and inflammatory processes, and most pathologic conditions (cancer, atherosclerosis, and neurologic disorders) associated with Hp 2-2 are associated with inflammation. In aggregate, our data clearly show an association of Hp 2-2 with the presence of seizures in patients with epilepsy. At present we do not know the mechanism for this phenomenon. We hypothesize that a defective clearing system (such as Hp 2-2), which cannot effectively remove free hemoglobin after microhemorrhagic events in the central nervous system, leads to iron accumulation and increased oxidative stress in tissue. Therefore, enhanced oxidative stress with minimum antioxidant defense can lead to tissue injury and inflammation, which may have a role in the etiology of seizure attacks in this patient population. More work is needed for better understanding of the role of haptoglobin in the pathophysiology of epilepsy. References 1 Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996 ; 334 : 168 -175. Crossref Search ADS PubMed 2 Brodie MJ, Shorvon SD, Canger R, Halasz P, Johannessen S, Thompson P, et al. Commission on European Affairs: appropriate standards of epilepsy care across Europe: ILEA. Epilepsia 1997 ; 38 : 1245 -1250. Crossref Search ADS PubMed 3 Loiseau P, Jallon p. Post-traumatic epilepsy. Prog Neurol Surg 1981 ; 10 : 323 -328. Crossref Search ADS PubMed 4 Rosen AD, Frumin NV. Focal epileptogenesis after intracortical hemoglobin injection. Exp Neurol 1979 ; 66 : 277 -284. Crossref Search ADS PubMed 5 Hammond EJ, Ramsay RE, Villarreal HJ, Wilder BJ. Effects of intracortical injection of blood and blood component in the electrocorticogram. Epilepsia 1980 ; 21 : 3 -14. Crossref Search ADS PubMed 6 Willmore LJ, Sypert GW, Munson J. Chronic focal epileptiform discharges induced by injection of iron into rat and cat cortex. Science 1978 ; 200 : 1501 -1503. Crossref Search ADS PubMed 7 Fairbanks V, Beutler E. Iron metabolism. Beutler E eds. Hematology, 6th ed 2000 : 295 -305 McGraw-Hill New York. . 8 Wassell J. Haptoglobin: function and polymorphism. Clin Lab 2000 ; 46 : 547 -552. PubMed 9 Javid J. Human haptoglobins. Curr Top Hematol 1978 ; 1 : 151 -192. PubMed 10 Black JA, Dixon GH. Amino-acid sequence of α chains of human haptoglobins. Nature 1968 ; 218 : 738 -741. 11 Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996 ; 42 : 1589 -1600. Crossref Search ADS PubMed 12 Gutteridge JM. The antioxidant activity of haptoglobin towards haemoglobin-stimulated lipid peroxidation. Biochim Biophys Acta 1987 ; 917 : 219 -223. Crossref Search ADS PubMed 13 Cid MC, Grant DS, Hoffman GS, Auerbach R, Fauci AS, Kleinman HK. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 1993 ; 91 : 977 -985. Crossref Search ADS PubMed 14 Bowman BH. Haptoglobin. Bowman BH eds. Hepatic plasma proteins 1993 : 159 -167 Academic Press San Diego. . 15 Arredouani M, Matthijs P, Van Hoeyveld E, Kasran A, Baumann H, Ceuppens JL, et al. Haptoglobin directly affects T cells and suppresses T helper cell type 2 cytokine release. Immunology 2003 ; 108 : 144 -151. Crossref Search ADS PubMed 16 Smithies O. Zone electrophoresis in starch gels: group variations in the serum proteins of normal adults. Biochem J 1955 ; 61 : 629 -641. Crossref Search ADS PubMed 17 Ledue TB, Weiner DL, Sipe J, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A, and mannose binding protein in human serum. Ann Clin Biochem 1998 ; 35 : 745 -753. Crossref Search ADS PubMed 18 Thompson KJ, Shoham S, Connor JR. Iron and neurodegenerative disorders. Brain Res Bull 2001 ; 55 : 155 -164. Crossref Search ADS PubMed 19 Sadrzadeh SM, Graf E, Panter SS, Hallaway PE, Eaton JW. Hemoglobin. A biologic Fenton reagent. J Biol Chem 1984 ; 259 : 14354 -14356. PubMed 20 Panter SS, Sadrzadeh SM, Hallaway PE, Haines JL, Anderson VE, Eaton JW. Hypohaptoglobinemia associated with familial epilepsy. J Exp Med 1985 ; 161 : 748 -754. Crossref Search ADS PubMed 21 Repine JE, Eaton JW, Anders MW, Hoidal JR, Fox RB. Generation of hydroxyl radical by enzymes, chemicals and human phagocytes in vitro: detection using the anti-inflammatory agent, dimethyl sulfoxide (DMSO). J Clin Invest 1979 ; 64 : 1642 -1651. Crossref Search ADS PubMed 22 Rosen H, Klebanoff SJ. Role of iron and ethylenediaminetetraacetic acid in the bactericidal activity of a superoxide anion-generating system. Arch Biochem Biophys 1979 ; 208 : 512 -519. 23 Sadrzadeh SM, Eaton JW. Hemoglobin-mediated oxidant damage to the central nervous system requires endogenous ascorbate. J Clin Invest 1988 ; 82 : 1510 -1515. Crossref Search ADS PubMed 24 Sadrzadeh SMH, Anderson DK, Panter SS, Hallaway PE, Eaton JW. Hemoglobin potentiates central nervous system damage. J Clin Invest 1987 ; 79 : 662 -664. Crossref Search ADS PubMed 25 Gabray C, Kushner I. Acute phase proteins and other systemic responses to inflammation [Erratum in: N Engl J Med 1999;340:1376]. N Engl J Med 1999 ; 340 : 448 -454. Crossref Search ADS PubMed 26 Langlois MR, Martin ME, Boelaert JR, Beaumont C, Taes YE, De Buyzere ML, et al. Haptoglobin phenotype 2–2 overrepresentation in Cys282Tyr hemochromatotic patients. J Hepatol 2001 ; 35 : 707 -711. Crossref Search ADS PubMed 27 Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, et al. Identification of the haemoglobin scavenger receptor. Nature 2001 ; 409 : 198 -201. Crossref Search ADS PubMed 28 Roguin A, Ribichini F, Ferrero V, Matullo G, Herer P, Wijns W, et al. Haptoglobin phenotype and the risk of restenosis after coronary artery stent implantation. Am J Cardiol 2002 ; 89 : 806 -810. Crossref Search ADS PubMed 29 Raley MJ, Loegering DJ. Role of an oxidative stress in the macrophage dysfunction caused by erythrophagocytosis. Free Radic Biol Med 1999 ; 27 : 1455 -1464. Crossref Search ADS PubMed © 2004 The American Association for Clinical Chemistry This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
TI - Haptoglobin Phenotypes in Epilepsy
JF - Clinical Chemistry
DO - 10.1373/clinchem.2003.028001
DA - 2004-06-01
UR - https://www.deepdyve.com/lp/oxford-university-press/haptoglobin-phenotypes-in-epilepsy-LWw0qJZAXc
SP - 1095
VL - 50
IS - 6
DP - DeepDyve
ER -